Lead Product(s): Bispecific antibodies
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Tavotek Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 25, 2020
The objective of the agreement is to develop a novel first-in-class immune-modulator bispecific antibody for auto-immune and inflammatory-related conditions, using DuoBody® technology, proprietary platform of Genmab A/S of Denmark.